Pediatric Brain Cancer Breakthrough: New Drug Delivery Research Targets Deadly Childhood Tumors

Why Is Pediatric Brain Cancer So Difficult to Treat?

Brain and central nervous system tumors are the most common solid tumors in children and, according to the National Cancer Institute, are the leading cause of cancer-related death in individuals under age 20. Unlike many adult cancers, pediatric brain tumors are biologically distinct, arise in developing tissue, and often respond poorly to therapies originally developed for adults. Tumor types such as diffuse intrinsic pontine glioma (DIPG), medulloblastoma, and high-grade gliomas carry particularly poor prognoses.

A major obstacle in treating these cancers is the blood-brain barrier — a tightly regulated network of cells that protects the brain from circulating toxins but also prevents most systemic chemotherapy agents from reaching therapeutic concentrations in brain tissue. Even when drugs successfully cross the barrier, the developing pediatric brain is vulnerable to long-term neurocognitive toxicity from radiation and cytotoxic therapies, leaving survivors with lifelong impairments.

How Are Researchers Working to Improve Drug Delivery?

Pharmacy scientists at institutions including the UNC Eshelman School of Pharmacy are investigating nanotechnology-based drug carriers, convection-enhanced delivery, and molecularly targeted formulations intended to deliver chemotherapy or novel agents directly into brain tumor tissue while sparing healthy developing neurons. These approaches aim to reduce systemic toxicity and neurocognitive side effects, which are a major concern in pediatric survivors.

Parallel efforts across the pediatric oncology community are exploring immunotherapies, including CAR-T cell approaches for brain tumors, as well as agents targeting specific mutations such as H3K27M in diffuse midline gliomas. Combining improved delivery platforms with these molecularly targeted therapies could significantly expand the therapeutic arsenal against tumors that, for decades, have had few effective options.

What Does This Mean for Families and Future Care?

For families facing a pediatric brain tumor diagnosis, current standard of care generally involves some combination of surgery, radiation, and chemotherapy, depending on tumor type, location, and age. Five-year survival varies widely by diagnosis — while some medulloblastomas are curable, outcomes for DIPG and other high-grade pediatric brain tumors remain dismal, with most children surviving less than two years after diagnosis.

Ongoing pharmaceutical research, including drug delivery innovations studied at academic centers like UNC, represents an important pipeline of future treatment options. Families are generally encouraged to discuss participation in clinical trials with their pediatric neuro-oncology team, as trials remain a critical route to accessing emerging therapies for diseases with limited standard treatment options.